Evidence map›Paper›PMID 25258515›Full record

ArticleDrug design, development and therapy2014

Enhanced bioavailability and anthelmintic efficacy of mebendazole in redispersible microparticles with low-substituted hydroxypropylcellulose.

Paloma Marina de la Torre-Iglesias, Juan José García-Rodriguez, Guillermo Torrado, Susana Torrado, Santiago Torrado-Santiago, Francisco Bolás-Fernández

Abstract read
In one paragraph

Article in Drug design, development and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Paloma Marina de la Torre-IglesiasDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Complutense University, Madrid, Spain ; Institute of Industrial Pharmacy, Complutense University, Madrid, Spain.
Juan José García-RodriguezDepartment of Parasitology, Faculty of Pharmacy, Complutense University, Madrid, Spain.
Guillermo TorradoDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Alcala University, Alcala de Henares (Madrid), Spain.
Susana TorradoDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Complutense University, Madrid, Spain ; Institute of Industrial Pharmacy, Complutense University, Madrid, Spain.
Santiago Torrado-SantiagoDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Complutense University, Madrid, Spain ; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
Francisco Bolás-FernándezDepartment of Parasitology, Faculty of Pharmacy, Complutense University, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMebendazole (MBZ) is an extremely insoluble and therefore poorly absorbed drug and the variable clinical results may correlate with blood concentrations. The necessity of a prolonged high dose treatment of this drug increases the risk of adverse effects.

methodsIn the present study we prepared redispersible microparticles (RDM) containing MBZ, an oral, poorly water-soluble drug, in different proportions of low-substituted hydroxypropylcellulose (L-HPC). We investigated the microparticulate structures that emerge spontaneously upon dispersion of an RDM in aqueous medium and elucidated their influence on dissolution, and also on their oral bioavailability and therapeutic efficiency using a murine model of infection with the nematode parasite Trichinella spiralis.

resultsElevated percentages of dissolved drug were obtained with RDM at 1:2.5 and 1:5 ratios of MBZ: L-HPC. Thermal analysis showed an amorphization of MBZ in the RDM by the absence of a clear MBZ melting peak in formulations. The rapid dissolution behavior could be due to the decreased drug crystallinity, the fast dissolution time of carriers as L-HPC, together with its superior dispersibility and excellent wetting properties. RDM-1:2.5 and RDM-1:5 resulted in increased maximum plasma concentration and area(s) under the curve (AUC)0-∞ values. Likewise, after oral administration of the RDM-1:2.5 and RDM-1:5 the AUC0-∞ were 2.67- and 2.97-fold higher, respectively, compared to those of pure MBZ. Therapeutic activity, assessed on the Trichinella spiralis life cycle, showed that RDM-1:5 was the most effective in reducing the number of parasites (4.56-fold) as compared to pure MBZ, on the encysted stage.

conclusionTHE MBZ: L-HPC RDM might be an effective way of improving oral bioavailability and therapeutic activity using low doses of MBZ (5 mg/kg), which implies a low degree of toxicity for humans.

Indexed as

Administration, OralAnimalsAnthelminticsBiological AvailabilityCelluloseDisease Models, AnimalLife Cycle StagesMebendazoleMiceMice, Inbred StrainsParticle SizeSolubilitySurface PropertiesTrichinella spiralisTrichinellosisAnthelminticsCellulosehydroxypropylcelluloseMebendazoleanthelmintic activitybenzimidazole carbamatesin vitro dissolutionpharmacokineticsredispersible microparticlesTrichinella spiralis

Identifiers

PMID25258515
PMCPMC4174045

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.